LHDX
Lucira Health, Inc.
Set alert
52-week range unavailable
- Open
- 0.4852
- Prev close
- 0.4523
- Mkt cap
- 18.36M
- Vol
- 36.26M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.431
- High
- 0.578
- Forward P/E
- -0.94
- Beta
- 3.76
- Short ratio
- 0.24
- Inst. own
- 23.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 9, 2023
- 50-d avg
- 0.354759
- 200-d avg
- 1.21
- 1y target
- 0.50
Key statistics
- Market cap
- 18.36M
- Enterprise value
- 26.68M
- Trailing P/E
- 0.00
- Forward P/E
- -0.94
- PEG ratio
- 0.00
- Price / sales
- 0.09
- Price / book
- 0.30
- EPS (TTM)
- -3.14
- Beta
- 3.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -67.54%
- Revenue (TTM)
- 212.13M
- Revenue growth
- 129.60%
- Free cash flow
- -49.88M
- Total cash
- 39.77M
- Total debt
- 48.09M
- Return on equity
- -112.43%
- Shares outstanding
- 40.60M
- Short % of float
- 3.77%
- 50-day average
- 0.354759
- 200-day average
- 1.21
Analyst view
Consensus: hold
Next earnings
Mar 9, 2023
Expected Mar 9, 2023. Consensus EPS estimate -0.40.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 9, 2023 | Dec 1, 2022 | -0.33 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.38 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.30 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.08 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -0.55 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -0.51 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 4, 2021 | William Blair | down | Outperform | Market Perform |
| Apr 13, 2021 | B of A Securities | down | Buy | Underperform |
| Mar 2, 2021 | B of A Securities | init | — | Neutral |
| Mar 2, 2021 | William Blair | init | — | Outperform |
About Lucira Health, Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- lucirahealth.com
News
- Why Is Lucira Health (LHDX) Stock Down 14% Today?
- Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
- Penny Stocks: The Importance of Liquidity and Volume
- Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week
- Lucira Health shares rise more than 300% on FDA authorization of at-home combination COVID-19 and flu test
- Why Is Lucira Health (LHDX) Stock Up 237% Today?
- Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test
- Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Why Is Lucira Health (LHDX) Stock Down 34% Today?
- 5 Big Winners as Wall Street Wraps Up Strong January Gains
Your note
Sign in to keep a note on LHDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN ANTHONY JOSEPH | Chief Operating Officer | Sale | Dec 19, 2022 | 144,925 |
| COLLINS KEVIN WALTER | Officer | Sale | Nov 24, 2022 | 346,722 |
| ENGELSON ERIK T. | Chief Executive Officer | Purchase | Sep 14, 2022 | 321,387 |
| GEORGE DANIEL | Chief Financial Officer | Sale | Sep 15, 2022 | 46,011 |
| HARTMANN HANSGREGORY C | Chief Operating Officer | Stock Award(Grant) | Jun 17, 2021 | 100,000 |
| KASHMOLAH GHAZI | Officer | Sale | Feb 15, 2023 | 134,075 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eclipse Ventures, LLC | 15.52% | 6,223,795 | 2.82M | Dec 30, 2022 |
| EPIQ Capital Group, LLC | 1.81% | 725,675 | 328.22K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 1.55% | 623,488 | 282.00K | Dec 30, 2022 |
| Citigroup Inc. | 1.09% | 436,840 | 197.58K | Dec 30, 2022 |
| Balyasny Asset Management LLC | 0.68% | 271,030 | 122.59K | Dec 30, 2022 |
| Morgan Stanley | 0.52% | 207,755 | 93.97K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.16% | 464,745 | 210.20K | Sep 29, 2022 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.80% | 320,200 | 144.83K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.32% | 130,090 | 58.84K | Sep 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.28% | 110,500 | 49.98K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.12% | 46,406 | 20.99K | Nov 29, 2022 |
| iShares Micro Cap ETF | 0.10% | 38,198 | 17.28K | Dec 30, 2022 |